Association Between Arterial Wall Uptake of Fluorodeoxyglucose on PET Imaging and sRAGE

Arteriosclerosis is a dynamic inflammatory disorder. Recently, FDG-PET CT is emerging diagnostic tool of non-invasive technique to detect vulnerable atherosclerotic plaque. And there are arising evidence that sRAGE(soluble Receptor for Advanced glycation End Product) is correlated with metabolic risk. So the investigators will investigate association between sRAGE and FDG-PET uptake in large artery in healthy patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

sRAGE Level SUV and TBR Levels in FDG PET

Age range

16 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis od type 2 DM

Exclusion criteria

Type 1 DM
Gestational Diabetes
Severe Liver or Renal disease
Diagnosis of cancer
Trauma
Acute infection or inflammatory disease
Acute vasculitis or history of vasculitis
Pregnant or Lactating women
Dyslipidemia(active state)
Cardiovascular disease or history of CVD
Chronic obstructive pulmonary disease
Any patient by judge of investigator

Sponsors and collaborators

Lead sponsor

Korea University

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Nov 30, 2009
Registry last updated: Apr 6, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.